Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a supplement stop hair loss? new study investigates

NCT ID NCT07358403

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a dietary supplement (capsules and drink) could reduce hair loss in 240 adults with androgenetic alopecia or chronic telogen effluvium. Participants took the supplement or a placebo daily for 6 months. Researchers measured hair density and asked about product satisfaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

240 people

The number who actually took part.

Started

Nov 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 62 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy female and male subjects, including at least 70% female subjects aged over 30 years old ✓ Caucasian ethnicity * Aged between 18 and 62 years old (extreme included) * 50% of subjects with chronic telogen effluvium (stage from 2 to 4, according to Sinclair scale for female pattern hair loss in women and modified Sinclair scale for female pattern hair loss in men) * 50% of subjects with androgenetic alopecia (AGA): female subjects Ludwig scale (score I-II) and male subjects Hamilton- Norwood scale (vertex II-III) * Subjects aware of the study procedures and having signed an informed consent form * Subjects registered with National Health Service (NHS) * Subjects certifying the truthfulness of the personal data disclosed to the investigator * Subjects able to understand the language used in the investigation and to respect the instructions given by the investigator as well as able to respect the study constraints and specific requirements * The pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) should be stable for at least one month without any changes expected or planned during the study * Commitment not to change the daily routine or the lifestyle * Subject informed about the study procedures and having signed the privacy policy Exclusion Criteria: * Subjects who do not fit the inclusion criteria. * Subjects with acute or chronic diseases able to interfere with the outcome of the study or that are considered dangerous for the subject or incompatible with the study requirements * Subjects participating or planning to participate in other clinical trials * Subjects deprived of freedom by administrative or legal decision or under guardianship * Subjects not able to be contacted in case of emergency * Subjects admitted to a health or social facility * Subjects planning a hospitalization during the study * Subjects who participated in a similar study without respecting an adequate washout period (3 months) * Alimentary/Eating disorders (i.e., bulimia, psychogenic eating disorders, etc.) * Food allergy or food intolerances * Impaired immune system due to i-mmunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications * Subjects who have any type of gastrointestinal disease or disorders (Chrons disease, colitis, irritable bowel syndrome, intestinal malabsorption) * Pharmacological treatment (topic or systemic) known to interfere with the tested product or having effect on metabolism (e.g.: anticoagulants, antidepressants, drugs used to lower cholesterol levels, antiviral drugs and beta-blockers) * Subjects having frequent stomach burn * Cosmetic treatment known to interfere with the tested product (e.g.: anti-hair loss shampoo, antihair loss food supplements, anti-hair loss serum) during the study and in the last 3 months before study start * Subjects who intends to carry out any straightening, permanent or other treatments on hair (hair botox,etc) * Subjects with drandruff, seborrheic dermatitis or any other hair condition * Subjects having a skin disease or condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements * Subjects that have shown allergies or sensitivity to cosmetic products, drugs, patch or medical devices * Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (for the women of childbearing potential)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenetic alopecia (AGA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Complife Italia

    San Martino Siccomario, Milan, 27028, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.